← Human Trials & Peer-Reviewed Studies
Bisphosphonates in combination with alendronate sodium increase bone mineral density and modulate IL-6, TNF-α, and IGF-1 in patients with osteoporosis
Plain-language guide to PMID 40013964 (2025): randomized controlled trial study of IGF-1 LR3 in 94 patients, osteoporosis and bone density.
Key Facts
- PMID
- 40013964
- Journal
- International journal of clinical pharmacology and therapeutics
- Year
- 2025
- Study type
- Randomized Controlled Trial
- Authors
- Gu X et al. (4 authors)
- DOI
- 10.5414/CP204706
What This Study Did, in Plain Language
What Was Tested
Researchers studied IGF-1 LR3 in the context of osteoporosis and bone density in this randomized controlled trial publication.
To assess the effects of bisphosphonates (zoledronic acid injection) plus alendronate sodium on bone mineral density (BMD) and levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and insulin-like growth factor I (IGF-I) in patients with osteoporosis.
Who Took Part
The abstract describes 94 patients taking part.
The age groups tagged for this paper are middle-aged adults, older adults and people over 80, both men and women.
A total of 94 patients recruited from osteoporosis patients hospitalized in the period October 2021 to December 2022 were assigned to either a control group or an observation group using a random number table.
How the Study Was Run
The researchers set it up as a randomized study.
Because people in this IGF-1 LR3 study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
The control group was treated with alendronate sodium alone, whereas the observation group received zoledronic acid injection in combination with alendronate sodium administered orally.
What Was Measured
Topics PubMed links to this paper include Alendronate, Bone Density, Bone Density Conservation Agents, Insulin-Like Growth Factor I, Interleukin-6, Osteoporosis and Tumor Necrosis Factor-alpha.
What This Means in Plain Language
The paper is a randomized study of IGF-1 LR3 in 94 patients in people with osteoporosis and bone density.
Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2025 (International journal of clinical pharmacology and therapeutics), a journal based in Germany.
More context: the IGF-1 LR3 compound page, Osteoporosis and bone density research.
Our Notes on the Compound
IGF-1 LR3: A modified IGF-1 analog that escapes binding proteins, so it stays active ≥24 h.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.